Skip to main content
SpringerLink
Log in

Lomustin und Temozolomid in Kombination mit Bestrahlung

Neue Option in der Erstlinientherapie bei Patienten mit Glioblastom mit methyliertem MGMT-Promotor

Lomustine and temozolomide in combination with radiotherapy

New treatment option for patients with MGMT promoter methylated Glioblastoma

  • Literatur kommentiert
  • Published:
Strahlentherapie und Onkologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Chinot OL, Wick W, Mason W et al (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709–722

    Article  CAS  PubMed  Google Scholar 

  2. Gilbert MR, Dignam JJ, Armstrong TS et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699–708

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Stupp R, Hegi ME, Gorlia T, Erridge SC et al (2014) Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): A multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 15(10):1100–1108. https://doi.org/10.1016/S1470-2045(14)70379-1

    Article  CAS  PubMed  Google Scholar 

  4. Weller M, Butowski N, Tran DD, Recht LD et al (2017) Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol 18(10):1373–1385. https://doi.org/10.1016/S1470-2045(17)30517-X

    Article  CAS  PubMed  Google Scholar 

  5. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996

    Article  CAS  PubMed  Google Scholar 

  6. Herrlinger U, Rieger J, Koch D et al (2006) Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. J Clin Oncol 24(27):4412–4417

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Univ.-Klinik für Radioonkologie und Strahlentherapie, Stephanstraße 9a, 04103, Leipzig, Deutschland

    Clemens Seidel &  Rolf-Dieter Kortmann

Authors
  1. Clemens Seidel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rolf-Dieter Kortmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Clemens Seidel.

Ethics declarations

Interessenkonflikt

C. Seidel und R.-D. Kortmann geben an, dass kein Interessenkonflikt besteht.

Additional information

Originalpublikation

Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U et al for the Neurooncology Working Group of the German Cancer Society (2019) Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase III trial. Lancet. Feb 16; 393 (10172):678–688. https://doi.org/10.1016/S0140-6736(18)31791-4 (Epub 2019 Feb 14)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Seidel, C., Kortmann, RD. Lomustin und Temozolomid in Kombination mit Bestrahlung. Strahlenther Onkol 195, 855–856 (2019). https://doi.org/10.1007/s00066-019-01487-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00066-019-01487-w

Search

Navigation